Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Bio-Rad launches anti-ranibizumab antibodies

Bio Rad logo 9.9.18Bio-Rad Laboratories, Inc has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A).

Ranibizumab is used for the treatment of wet age-related macular degeneration (AMD), a common form of age-related vision loss, and for macular edema and diabetic retinopathy. The anti-ranibizumab antibodies are inhibitory, non-inhibitory, and drug-target-complex-specific antibodies designed for use in pharmacokinetic (PK) and immunogenicity assays for ranibizumab and its biosimilars.

“We are excited to introduce four anti-ranibizumab antibodies that are highly specific for ranibizumab or the ranibizumab-VEGF-A complex,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “Ranibizumab is a Fab fragment drug and is present at very low levels in patient samples, which presents challenges for PK assay design and sensitivity. The high-affinity ranibizumab-VEGF-complex-specific antibody is unique to Bio-Rad and overcomes those challenges by enabling the development of a PK antigen capture assay to measure free drug.”

Bio-Rad’s anti-idiotypic antibodies are generated using Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. Bio-Rad says the recombinant production method also ensures a consistent and secure supply.

The antibodies are approved for in-vitro research and for commercial applications of in-vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.

For further information about Bio-Rad’s anti-ranibizumab antibodies visit www.bio-rad-antibodies.com/anti-ranibizumab-antibody-lucentis.html

Last modified onSunday, 09 September 2018 05:37